Brief: Calliditas Announces Positive Results Of Phase 2 Head, Neck Cancer Trial With Setanaxib
06/05/2024 07:07
May 6 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* ANNOUNCES POSITIVE TOPLINE RESULTS OF PHASE 2 HEAD AND NECK CANCER TRIAL WITH LEAD NOX
INHIBITOR
CANDIDATE, SETANAXIB
* ANALYSIS SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PROGRESSION-FREE SURVIVAL (PFS),
AS
WELL AS IN OVERALL SURVIVAL (OS)
* STATISTICALLY SIGNIFICANT CHANGES IN TUMOR BIOLOGY CONSISTENT WITH MECHANISM OF ACTION OF
SETANAXIB
Source text for Eikon: ID:nWkr14bpPP
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations